+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

China Assisted Reproduction Market Insight Report, 2021-2025

  • ID: 5359663
  • Report
  • May 2021
  • Region: China
  • 136 pages
  • AEI Research

FEATURED COMPANIES

Assisted ReproductiveTechnology (ART) refers to the technology of artificial manipulation of gametes (sperm and eggs), zygotes (fertilized eggs) and embryos to achieve the purpose of conception.

Living environment, work pressure, and delayed age of first marriage and first childbearing lead to an increase in infertility rate year by year, and the incidence of female infertility in China ranges from 12.5% to 15%. By the end of 2019, there were about 308 million women aged 21-49 in China, that is, about 38.5 million-46.2 million women of school age suffered from infertility. In addition, there were more than 48 million infertile couples in China.

There are currently 517 medical institutions approved to carry out ART services in China. According to the total number of ART service cycles in 2020, the average number of service cycles per institution is more than 2,600. Among them, public assisted reproductive medical institutions accounted for more than 90%, and the service volume of public medical institutions accounted for more than 95% due to their large scale and high-quality doctors. According to the license qualifications of all assisted reproductive medical institutions, there are currently 396 institutions that can provide IVF services, and only 70 institutions that can provide PGT services, accounting for 14% of all assisted reproductive institutions.

According to field investigation and interview, the cost of IVF is about 60,000 yuan per cycle, and that of AI is about 5,000 yuan per cycle. At present, 9.6 million infertile couples need ART services, and the ratio of IVF to AI is 19:7, so the market demand scale of IVF is 421.2 billion yuan, that of AI is 12.9 billion yuan, and that of the whole ART market reaches 434.1 billion yuan. In 2020, domestic IVF service scale will be 57.1 billion yuan, AI service scale will be 1.8 billion yuan, and ART total service scale will be 58.9 billion yuan, which means that there is still a potential market space of 375.2 billion yuan in China.

To sum up, China's assisted reproductive industry has three characteristics: great market development potential, uneven distribution of assisted reproductive service resources, and strong dependence on imports of assisted reproductive medicines and instruments. Great market development potential: 9.6 million infertile couples, with a market demand gap of 375.3 billion yuan to be met. Uneven distribution of auxiliary reproductive service resources: public auxiliary reproductive medical institutions account for more than 90%, only 70 have the qualification of third-generation IVF service, the eastern coastal provinces have sufficient auxiliary reproductive service resources, while the central and western provinces lack auxiliary reproductive resources. The import dependence of auxiliary reproductive medical equipment is strong: 95% of auxiliary reproductive high-value consumable medical equipment and 80% of auxiliary reproductive medicines depend on imports, and the degree of localization is low.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

1 industry profile: great market potential, unbalanced distribution of service resources, and low degree of localization of medical equipment
1.1 serving 9.6 million infertile couples, with public institutions taking the lead
1.2 The industrial chain pattern has been established, but the localization of upstream medical equipment is low
1.3 3752 billion supply and demand gap depicts the blue ocean of domestic alternative market

2 Domestic substitution: phased and progressive substitution, and localization of medical equipment has a long way to go
2.1 Domestic substitution of medical devices: Assisted reproductive fluids and PGT reagents become the core of substitution
2.2 domestic substitution of drugs: ovulation-promoting drugs become the core of substitution
2.3 case analysis: weituo biology

3 Service empowerment: Based on laboratory construction, create an all-round forward empowerment matrix
3.1 Auxiliary reproductive medical service resources are unevenly distributed, and service capabilities are uneven
3.2 Forward empowerment of upstream enterprises to enhance the service capacity of downstream medical institutions
3.3 Case Analysis: Yikang Gene

4 Future trend: technology and policy are driven, and digital technology builds intelligent service
4.1 Technological innovation and examination and approval reform promote the accelerated expansion of domestic brand market share
4.2 Construction of Digital Ecological Base of Assisted Reproductive Industry Chain in New Medical Infrastructure
4.3 Operation management and channel construction have become the optimal strategy for differentiated development of private assisted reproduction

Selected Charts
Figure 1 Selection and distribution of treatment methods for infertility among doctors in China
Figure 2 ART mainstream technology and applicable objects
Figure 3 Total number of domestic ART service cycles from 2016 to 2020
Figure 4 Distribution of service capacity of assisted reproductive medical institutions in China
Figure 5 Number distribution of auxiliary reproductive medical institutions in different provinces
Figure 6 Ecological pattern of assisted reproductive industry chain
Figure 7 Potential scale of China's assisted reproductive market
Figure 8 Distribution of IVF costs and sources of equipment and drugs
Figure 9 IVF services and supporting medical devices
Figure 10 Market size of IVF medical devices from 2016 to 2023
Figure 11 Product certification of domestic IVF medical device enterprises (partial)
Figure 12 Comparison between vitrification and programmed freezing
Figure 13 Comparison of three screening types of PGT
Figure 14 Schematic diagram of domestic substitution status of medical devices
Figure 15 Domestic alternative path diagram of assisted reproductive medical devices
Figure 16 Drug use in main links of assisted reproduction
Figure 17 Market size and growth rate of IVF drugs from 2016 to 2023
Figure 18 Distribution of market share of domestic and foreign enterprises in IVF drug market in 2020
Figure 19 Company Assisted Reproductive Product System
Figure 20 Application process and main conditions of assisted reproductive license
Figure 21 Assisting reproductive upstream enterprises to forward empower downstream enterprises
Figure 22 Schematic diagram of assisted reproductive laboratory service technology platform
Figure 23 Full-process service of assisted reproductive medical institutions
Figure 24 Referral Platform for Assisted Reproductive Cloud Consultation
Figure 25 Multi-agent collaborative mode of assisted reproductive medical service resources
Figure 26 Solution of clinical application scenario of reproductive health
Figure 27 Changes of domestic/foreign market share of auxiliary reproductive medical equipment market
Figure 28 New medical infrastructure solutions for the whole chain of assisted reproductive industry chain
Figure 29 Comparison of development paths between public assisted reproductive medical institutions and private assisted reproductive medical institutions
Table 1 Main functions of IVF medical devices
Table 2 Products of IVF Medical Device Enterprises Abroad
Table 3 Comparison of many indexes between morphology and PGT embryo transfer
Table 4 IVF medication represents enterprise products and market share
Table 5 Clinical trial effect of vitrification freezing/thawing solution
Table 6 Monitoring Scenes of Intelligent Monitoring System in Assisted Reproductive Laboratory
Note: Product cover images may vary from those shown
  • Topchoice Medical Co.,Inc.
  • Jinxin Fertility Group Limited
  • YikonGenomics
Note: Product cover images may vary from those shown
Adroll
adroll